Real-world data back palopegteriparatide for hypoparathyroidism
In a 92-patient Greek cohort, the long-acting PTH replacement normalised calcium and phosphate and freed 58% of patients from calcium and vitamin D pills — echoing the trials, over a short follow-up.
The first real-world results for palopegteriparatide, a long-acting parathyroid hormone replacement approved for chronic hypoparathyroidism, broadly confirm what its clinical trials showed: in a 92-patient Greek cohort, the drug normalised blood calcium and phosphate and let 58% of patients stop their calcium and active vitamin D supplements [s1]. The follow-up was short and the study had no control group, so it corroborates the trial evidence rather than extending it.
The condition, and the drug
Chronic hypoparathyroidism is a rare disorder in which the parathyroid glands fail to make enough parathyroid hormone (PTH), leaving patients with low blood calcium and high phosphate [s1]. Conventional treatment — lifelong high-dose calcium and activated vitamin D — controls symptoms imperfectly and carries its own long-term costs, including high urinary calcium and kidney risk [s1]. Palopegteriparatide, marketed as Yorvipath, is a prodrug that releases PTH(1-34) slowly to mimic the hormone's natural levels; the US Food and Drug Administration approved it in August 2024 [s3]. Its pivotal evidence is the phase 3 PaTHway trial, whose 52-week results showed the drug maintaining normal calcium while patients came off conventional therapy [s2].
The open question with any drug approved on a single controlled trial is whether the benefit holds up when ordinary clinics prescribe it to ordinary patients. The PaTH REAL study is an early attempt to answer that.
What PaTH REAL found
PaTH REAL was a multicentre, prospective cohort study across tertiary referral hospitals in Greece, registered as NCT07299838 [s1]. It followed 92 adults with chronic hypoparathyroidism — 79 women and 13 men — who had previously been on either recombinant human PTH(1-84) or conventional therapy and were switched to palopegteriparatide under national treatment guidelines [s1]. Patients were treated for a median of 6.5 months (range 2–14) [s1].
The biochemistry moved in the intended direction. Albumin-adjusted calcium rose from 8.14 mg/dL (SD 0.73) to 8.99 mg/dL (SD 0.94), and magnesium from 1.79 mg/dL (SD 0.17) to 1.96 mg/dL (SD 0.17), both with p<0.001 [s1]. Phosphate fell from 4.74 mg/dL (SD 0.97) to 4.02 mg/dL (SD 0.63) (p<0.001), and the calcium–phosphate product from 38.27 to 36.04 mg²/dL² (p=0.017) [s1]. Twenty-four-hour urinary calcium — a marker of the kidney strain that conventional therapy can cause — dropped from 245.7 mg (SD 125.5) to 164.5 mg (SD 88.3) per 24 hours (p<0.001) [s1].
The most tangible change for patients was in pill burden: 58% became independent of calcium supplements and alfacalcidol after a median of 30 days [s1]. Adverse events were mostly mild and transient [s1].
How much it adds
Read carefully, this is confirmation rather than new ground. The effects match the direction and rough magnitude of the PaTHway trial, which is what a real-world study is meant to check [s1][s2]. The value is in the setting — unselected clinic patients, several switching from an older PTH replacement — and in the fall in urinary calcium, which speaks to exactly the long-term kidney concern that motivates replacing conventional therapy [s1].
The limits are equally plain. Ninety-two patients is small, a median of 6.5 months is short for a condition treated for life, and the cohort came from a single country under one set of national guidelines [s1]. There was no control arm, so the before-and-after comparison cannot separate the drug's effect from changes in monitoring or co-treatment [s1]. And durability — whether calcium control and supplement independence hold over years, and whether the urinary-calcium benefit translates into fewer kidney stones or better kidney function — is not something a study of this length can show [s1]. The pivotal trial provides the controlled evidence; PaTH REAL shows that, early and in practice, the drug behaves as advertised.
This article is informational and does not constitute medical advice.
Sources
- [s1] Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study. European Journal of Endocrinology, 27 August 2026. https://doi.org/10.1093/ejendo/lvag145
- [s2] Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. Journal of Clinical Endocrinology & Metabolism, 17 March 2025. https://doi.org/10.1210/clinem/dgae693
- [s3] Yorvipath (palopegteriparatide) approval, NDA 216490. US Food and Drug Administration (Drugs@FDA), approved 9 August 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216490
Sources
- Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study — European Journal of Endocrinology , August 27, 2026
- Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial — Journal of Clinical Endocrinology & Metabolism , March 17, 2025
- Yorvipath (palopegteriparatide) approval, NDA 216490 — US Food and Drug Administration (Drugs@FDA) , August 9, 2024
Mitapivat cut transfusions in thalassaemia, but not for most patients
In a 258-patient phase 3 trial, the oral drug reduced transfusion needs in about 30% of adults with transfusion-dependent thalassaemia, versus 13% on placebo.
An on-demand pill for hereditary angioedema attacks clears the FDA
Sebetralstat was approved on 3 July for patients aged 12 and older. In its pivotal crossover trial, 76% of attacks treated with the 600 mg dose began to ease within 12 hours, against 49% on placebo.
Oral ralinepag cuts clinical worsening in pulmonary arterial hypertension
In the industry-funded ADVANCE OUTCOMES trial, the once-daily prostacyclin-pathway drug more than halved the risk of a first worsening event, but drove far more treatment discontinuations for side-effects.
FDA is deleting the word 'animal' from its safety-testing rules. What changes?
A direct final rule swaps 'animal' for 'nonclinical' across five parts of FDA's drug regulations. It adds no requirements, but signals a shift the agency began with monoclonal antibodies.